Research progress on IL-6/JAK/STAT3 in the development and treatment of prostate cancer

doi:10.16352/j.issn.1001-6325.2022.01.025

Abstract

Abstract: IL-6/JAK/STAT3 is one of the most significant signaling pathways activated by IL-6.IL-6 and p-STAT3 which are highly expressed in prostate cancer (PCa) tissue and metastatic tumors So this pathway may play a role in the occurrence of prostate cancer, promotion of malignant cell proliferation, invasion and metastasis of the tumor. It may also function in the development of castration resistance and drug resistance through activation androgen receptor(AR). The multiple roles of IL-6/JAK/STAT3 and its activated downstream factors in tumor progression provide a good basis for the development of chemotherapy drugs. Currently, many targeted inhibitors have been proved to be effective in inhibiting tumor progression and more effective drugs are expected to be developed.

Key words: prostate cancer, castration-resistant prostate cancer, interleukin-6, signal transducer and activator of transcription (STAT3)

CLC Number:

R737.25

CHEN Hao, CHEN Tao, WU Jing. Research progress on IL-6/JAK/STAT3 in the development and treatment of prostate cancer[J]. Basic & Clinical Medicine, 2022, 42(1): 159-162.

References

[1]Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71: 7-33.
[2]付振涛, 郭晓雷, 张思维, 等. 2015年中国前列腺癌发病与死亡分析[J]. 中华肿瘤杂志, 2020: 718-722.
[3]Rojas A, Liu G, Coleman I, et al. IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR[J]. Oncogene, 2011, 30: 2345-2355.
[4]Babon JJ, Lucet IS, Murphy JM, et al. The molecular regulation of Janus kinase (JAK) activation[J]. Biochem J, 2014, 462: 1-13.
[5]张锦锦, 唐慧. JAK/STAT3信号通路调控肿瘤及其相关生物功能的研究进展[J]. 基础医学与临床, 2017, 37: 1456-1460.
[6]Liu G, Zhang J, Frey L, et al. Prostate-specific IL-6 transgene autonomously induce prostate neoplasm through amplifying inflammation in the prostate and peri-prostatic adipose tissue[J]. J Hematol Oncol, 2017, 10: 14. doi: 10.1186/s13045-13016-10386-13047.
[7]Hobisch A, Rogatsch H, Hittmair A, et al. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue[J]. J Pathol, 2000, 191: 239-244.
[8]Handle F, Puhr M, Schaefer G, et al. The STAT3 inhibitor galiellalactone reduces IL6-mediated AR activity in benign and malignant prostate models[J]. Mol Cancer Ther, 2018, 17: 2722-2731.
[9]Don-Doncow N, Marginean F, Coleman I, et al. Expres-sion of STAT3 in prostate cancer metastases[J]. Eur Urol, 2017, 71: 313-316.
[10]Lee SO, Lou W, Johnson CS, et al. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway[J]. Prostate, 2004, 60: 178-186.
[11]Schroeder A, Herrmann A, Cherryholmes G, et al. Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling[J]. Cancer Res, 2014, 74: 1227-1237.
[12]Xu L, Chen X, Shen M, et al. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels[J]. Mol Oncol, 2018, 12: 269-286.
[13]Gu L, Talati P, Vogiatzi P, et al. Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experi mental prostate cancer metastases formation[J]. Mol Cancer Ther, 2014, 13: 1246-1258.
[14]Armakolas A, Dimakakos A, Loukogiannaki C, et al. IL-6 is associated to IGF-1Ec upregulation and Ec peptide secretion, from prostate tumors[J]. Mol Med, 2018, 24: 6.doi: 10.1186/s10020-10018-10003-z.
[15]Wang X, Lee SO, Xia S, et al. Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals[J]. Mol Cancer Ther, 2013, 12: 1026-1037.
[16]Thaper D, Vahid S, Kaur R, et al. Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer[J]. Sci Rep, 2018, 8: 17307.doi: 17310.11038/s41598-17018-35612-z.
[17]Hu F, Zhao Y, Yu Y, et al. Docetaxel-mediated auto-phagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3[J]. Cancer Lett, 2018, 416: 24-30.
[18]Chen X, Chen F, Ren Y, et al. IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2[J]. J Cancer Res Clin Oncol, 2019, 145: 1471-1484.
[19]Huang S, Liu Q, Liao Q, et al. Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression[J]. Cancer Sci, 2018, 109: 678-687.
[20]Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer[J]. Nat Rev Clin Oncol, 2018, 15: 234-248.
[21]Han Z, Wang X, Ma L, et al. Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in pr ostate cancer[J]. Oncotarget, 2014, 5: 8416-8428.
[22]Canesin G, Evans-Axelsson S, Hellsten R, et al. The STAT3 inhibitor galiellalactone effectively reduces tumor growth and metastatic spread in an orthotopic xenograft mouse model of prostate cancer[J]. Eur Urol, 2016, 69: 400-404.
[23]Hellsten R, Lilljebjörn L, Johansson M, et al. The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors[J]. Prostate, 2019, 79: 1611-1621.
[24]Lee JH, Kim C, Baek SH, et al. Capsazepine inhibits JAK/STAT3 signaling, tumor growth, and cell survival in prostate cancer[J]. Oncotarget, 2017, 8: 17700-17711.
[25]Wang X, Wang B, Zhou L, et al. Ganoderma lucidum put forth anti-tumor activity against PC-3 prostate cancer cells via inhibition of Jak-1/STAT-3 activity[J]. Saudi J Biol Sci, 2020, 27: 2632-2637.
[26]Ghandadi M, Sahebkar A. Curcumin: an effective inhibi-tor of interleukin-6[J]. Curr Pharm Des, 2017, 23: 921-931.